[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Dormond et al., 2007 - Google Patents

The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells

Dormond et al., 2007

View HTML @Full View
Document ID
1139948261490273306
Author
Dormond O
Madsen J
Briscoe D
Publication year
Publication venue
Journal of Biological Chemistry

External Links

Snippet

Recent studies have determined that mTOR mediates the activation of the protein kinase Akt in several cell types, but little is known about the association between mTOR and Akt in vascular endothelial cells. Furthermore, the functional significance of mTOR/Akt signaling …
Continue reading at www.jbc.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Similar Documents

Publication Publication Date Title
Dormond et al. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells
Sheng et al. Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells
Li et al. RIG-I modulates Src-mediated AKT activation to restrain leukemic stemness
Gross et al. Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation
Gao et al. mTOR drives its own activation via SCFβTrCP-dependent degradation of the mTOR inhibitor DEPTOR
Fallahian et al. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor‐positive and‐negative breast cancer cell lines
Yan et al. Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation
Hong et al. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation
Ishida et al. Induction of the cyclin-dependent kinase inhibitor p21Sdi1/Cip1/Waf1 by nitric oxide-generating vasodilator in vascular smooth muscle cells
Holbro et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
Meller et al. Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons
Yu et al. PTEN regulation by Akt–EGR1–ARF–PTEN axis
Sønder et al. IL-17-induced NF-κB activation via CIKS/Act1: physiologic significance and signaling mechanisms
Kim et al. Mediator is a transducer of Wnt/β-catenin signaling
Castro et al. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin-and farnesylation-dependent manner
Tan et al. Foxo3a inhibits cardiomyocyte hypertrophy through transactivating catalase
Fernandez et al. Regulation of internal ribosomal entry site-mediated translation by phosphorylation of the translation initiation factor eIF2α
Zhao et al. The islet β cell-enriched MafA activator is a key regulator of insulin gene transcription
Ren et al. Cyclin C/cdk3 promotes Rb-dependent G0 exit
Skeen et al. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner
Jung et al. NM23-H1 tumor suppressor and its interacting partner STRAP activate p53 function
Liu et al. Siah-1 mediates a novel β-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein
Neshat et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Li et al. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival
Dehner et al. Wnt signaling inhibits Forkhead box O3a-induced transcription and apoptosis through up-regulation of serum-and glucocorticoid-inducible kinase 1